DOCSLIB.ORG

Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19 Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Correspondence Neutralising antibody (median age 42 years [IQR 33–52]) after dropped below 40 on their later study activity against either one dose (n=149; median time visit about 3 months after their second after first dose=30 days [IQR 23–38]) or BNT162b2 dose. Published Online SARS-CoV-2 VOCs two doses (n=159; median time after To maximise population coverage, June 3, 2021 https://doi.org/10.1016/ second dose=28 days [IQR 21–37]) of the UK extended the interval B.1.617.2 and B.1.351 by S0140-6736(21)01290-3 BNT162b2 (Pfizer–BioNTech) against between the two BNT162b2 doses. BNT162b2 vaccination five SARS-CoV-2 strains: a strain with Although this might have had a the original spike sequence (Wild- limited impact of protection against The SARS-CoV-2 B.1.617.2 Variant type); a strain with an Asp614Gly parental SARS-CoV-2 strains or the of Concern (VOC), first detected in mutation isolated during the first B.1.1.7 variant, the potential impact India, is now dominant in the UK, wave of infection in the UK, in 2020 on protection from other VOCs is having rapidly1 displaced the B.1.1.7 (D614G); and VOCs B.1.617.2, B.1.351 poorly understood. We found that strain2 that emerged in the UK with (first detected in South Africa in late neutralisation of VOCs was markedly the second COVID-19 wave in late 2020), and B.1.1.7. different after only one dose of 2020. The efficacy of currently licensed Two doses of BNT162b2 elicited BNT162b2 (appendix p 2): although COVID-19 vaccines against B.1.617.2 ELISA-detected anti-Wild-type spike 177 (95%) of 186 participants tested is unknown; although it possesses antibodies in all participants, and NAb positive for anti-spike antibodies by 12 mutations in its spike protein activity against all strains, including the ELISA and mounted a detectable NAb relative to the wildtype SARS-CoV-2 three VOCs tested, in all except six (3%) response against Wild-type (median first detected in Wuhan, China, in and nine (5%) of 159 participants who IC50=68 [IQR 42–140]) and D614G December, 2019, B.1.617.2 lacks lacked NAb activity against B.1.617.2 (median IC50=71 [IQR 46–111]), median mutations at amino acid positions 501 and B.1.351, respectively (appendix NAbTs against all VOCs were below or 484 in its ACE2 receptor-binding p 2). NAbTs of sera correlated well the quantitative limit of detection. domain, commonly associated with between Wild-type and variants Stratification of NAbTs into three VOCs (appendix p 2) or escape from (appendix p 2; RS>0·82, p<2 × 10⁻¹⁶), groups (IC50 low [<40], medium See Online for appendix neutralising antibodies (NAbs). as well as between VOCs (B.1.617.2 [40–256], high [>256]) and assessment To determine vaccine-induced NAb vs B.1.351: RS=0·85, p<2 × 10⁻¹⁶). of the significance of the shift in their escape by B.1.617.2 and compare However, NAbTs were 5·8-fold reduced distribution relative to Wild-type by activity to previous strains with against B.1.617.2 relative to Wild-type ordered logistical regression was more existing estimates for population- (95% CI 5·0–6·9), significantly more informative (appendix p 2). Whereas based vaccine efficacy, we carried reduced than against B.1.1.7 (2·6-fold only 39 (21%) of 186 samples had out an initial analysis of the Legacy vs Wild-type, 95% CI 2·2–3·1), and on a low NAbTs against Wild-type, this study, established in January, 2021, by similar order to the reduction observed proportion rose to 50% against B.1.1.7 University College London Hospital and against B.1.351 (4·9-fold vs Wild-type, (p=1·7 × 10⁻⁶) and further to 75% the Francis Crick Institute in London, 95% CI 4·2–5·7). against B.1.351 (p<3 × 10⁻¹⁶) and 68% UK, to track serological responses to Notably, across all variants, against B.1.617.2 (p<5 × 10⁻¹⁶). Notably, vaccination in prospectively recruited increased age significantly correlated the downwards shift in titres was also staff volunteers (appendix p 6). A with reduced NAbT (appendix p 2; significant when compared to B.1.1.7 detailed description of the methods, –0·33<RS<–0·27; 2·2 × 10⁻⁵<p<5·6 × 10⁻⁴), for B.1.351 (p=3·7 × 10⁻⁴) and B.1.617.2 including the clinical cohort, virus whereas no correlation was observed (p=1·2 × 10⁻⁵), confirming reduced culture conditions, genetic sequencing, for sex or body-mass index (appendix NAb activity against B.1.617.2 relative and neutralisation assays, and the p 4). NAbTs reduced over time after to the present B.1.1.7 strain after one statistical analysis are available in the administration of the second dose vaccine dose. Notably, participants appendix (p 8). The Legacy study was of BNT162b2: participants (n=14) with low NAbTs tend to be older than approved by London Camden and who attended an additional study those who produced medium or high Kings Cross Health Research Authority visit 8–16 weeks after their second responses (appendix p 2), and logistical Research and Ethics committee (IRAS BNT162b2 dose showed significantly regression analysis suggests age is a number 286469) and sponsored by reduced NAbTs against all variants significant factor in reduced NAbTs, University College London. (appendix p 2; 0·0002<p<0·0134). independent of strain in our samples Using a high-throughput live-virus While the final NAbTs against Wild- (appendix p 7; p=0.006), following a SARS-CoV-2 neutralisation assay type, D614G, and B.1.1.7 remained single dose of BNT162b2. Submissions should be (performance data are shown in the within the quantitative range of our These data, together with made via our electronic submission system at appendix p 3), we determined NAb assay (IC50>40), two participants’ NAbTs epidemiological data of B.1.617.2 http://ees.elsevier.com/ titres (NAbTs) in 250 participants against VOCs B.1.617.2 and B.1.351 growth, raise the possibility that thelancet/ www.thelancet.com Published online June 3, 2021 https://doi.org/10.1016/S0140-6736(21)01290-3 1 Correspondence this VOC presents a dual challenge result of factors aside from virus strain CSw reports grants from BMS, of reduced vaccine efficacy akin (appendix p 5), providing a basis to Ono-Pharmaceuticals, Boehringer-Ingelheim, Roche-Ventana, Pfizer and Archer Dx, unrelated to to the B.1.351 VOC, and increased understand observed vaccine efficacy this Correspondence; personal fees from transmissibility beyond the B.1.1.7 failure in other combinations of vaccine Genentech, Sarah Canon Research Institute, VOC. The impact of such a change and target population.6 Medicxi, Bicycle Therapeutics, GRAIL, Amgen, AstraZeneca, BMS, Illumina, GlaxoSmithKline, MSD, is challenging to predict: it remains In the case of single-dose recipients, and Roche-Ventana, unrelated to this difficult to assess precisely to what our data show that NAbTs are Correspondence; and stock options from Apogen extent the reduction in NAbTs we significantly lower against B.1.617.2 Biotech, Epic Biosciences, GRAIL, and Achilles observe will impact vaccine efficacy and B.1.351 VOCs relative to B.1.1.7, Therapeutics, unrelated to this Correspondence. All other authors declare no competing interests. and increase disease severity in a implying that although a single dose ECW, MW, SG, and DLVB contributed equally. vaccinated population, especially given might still afford considerably more GKa, CSw, SGan, and DLVB are joint senior authors. the multiple factors that contribute protection than no vaccination, RB and DLVB are members of the Genotype-to- Phenotype UK National Virology Consortium. to this process, such as long-lived single-dose recipients are likely Funding details and acknowledgments can be humoral immunity.3 to be less protected against these found in the appendix. All data (anonymised) and Nevertheless, a recent analysis of SARS-CoV-2 variants. These data full R code to produce all figures and statistical analysis presented in this Correspondence are For data and R code see https:// available NAb and vaccine efficacy therefore suggest that the benefits available online on Github. github.com/davidlvb/Crick- data4 has attempted to establish of delaying the second dose, in terms Emma C Wall, Mary Wu, Ruth Harvey, UCLH-Legacy-VOCs-2021-05 correlates of protection against earlier of wider population coverage and Gavin Kelly, Scott Warchal, strains of SARS-CoV-2 and, in the increased individual NAbTs after the 7 Chelsea Sawyer, Rodney Daniels, context of this model, our data suggest second dose, must now be weighed Philip Hobson, Emine Hatipoglu, that most participants that received against decreased efficacy in the Yenting Ngai, Saira Hussain, two doses of BNT162b2 would be short-term, in the context of the Jerome Nicod, Robert Goldstone, protected against B.1.617.2 infection spread of B.1.617.2.
Load more

Recommended publications
  • Since January 2020 Elsevier Has Created a COVID-19 Resource Centre with Free Information in English and Mandarin on the Novel Coronavirus COVID- 19
    Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Correspondence AZD1222-induced AZD1222 (n=50, median time after 186 [95%] of 195 against B.1.617.2). neutralising antibody first dose 41 days [IQR 30–51]) or Analysis of these data by ordered two doses of AZD1222 (n=63, median logistic regression confirmed vaccine Published Online activity against time after second dose 31 days type was associated with decreased June 28, 2021 https://doi.org/10.1016/ [IQR 19·5–46·0]; appendix p 7). The NAbTs, independent of SARS-CoV-2 SARS-CoV-2 Delta VOC S0140-6736(21)01462-8 median interval between doses was strain, in two-dose vaccine recipients The SARS-CoV-2 B.1.617.2 Delta 63 days (IQR 62·0–69·5). Consistent (p=0·0017; appendix p 4). variant of concern (VOC) continues with our previous findings,3 we included A single dose of AZD1222 generated to drive a sharp increase in COVID-19 a strain with the original spike sequence a broad range of NAb activity against cases in the UK, with a current doubling (Wildtype), a strain with an Asp614Gly Wildtype SARS-CoV-2 (appendix time of 3·5–16 days,1 consistent with mutation isolated during the first wave p 2).
    [Show full text]
  • The Francis Crick Institute Limited
    THE FRANCIS CRICK INSTITUTE LIMITED A COMPANY LIMITED BY SHARES ANNUAL REPORT AND FINANCIAL STATEMENTS 31 March 2019 Charity registration number: 1140062 Company registration number: 6885462 1 The Francis Crick Institute Limited annual report and financial statements 2019 Contents Chairman’s letter 3 Director’s introduction 4 Trustees’ report (incorporating the strategic report and 5 directors’ report) Independent auditor’s report 33 Consolidated statement of financial activities (incorporating 37 the income and expenditure account) Balance sheets 38 Consolidated cash flow statement 39 Notes to the financial statements 40 2 The Francis Crick Institute Limited annual report and financial statements 2019 Chairman’s letter As Chairman of the Crick, I am delighted with the progress the Institute has made across all of its strategic objectives in the last twelve months. Earlier this year, we met with the Crick’s core funders after their Establishment Review had assessed the progress made on setting up the Institute. The resulting strong endorsement is a testament to what has been achieved with regard to set-up, governance structures and strategic direction. This progress is borne out by recent successes which give me great confidence that the Crick is already beginning to deliver on its charitable mission to understand the fundamental biology that underlies health and disease. Over 400 papers were published by Crick researchers in the last year and it is a testament to the reputation of the Crick for high quality biomedical research that it continues be a magnet for talented Group Leaders and other staff. We are receiving around 100 applications for each Group Leader position, and over the last 12 months, had more than 30 applications for every postdoctoral fellowship and over 1700 graduate student applications for 49 PhD positions.
    [Show full text]
  • Reduced Antibody Cross-Reactivity Following Infection With
    RESEARCH ARTICLE Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains Nikhil Faulkner1,2†, Kevin W Ng1†, Mary Y Wu3†, Ruth Harvey4†, Marios Margaritis5, Stavroula Paraskevopoulou5, Catherine Houlihan5,6, Saira Hussain4,7, Maria Greco7, William Bolland1, Scott Warchal3, Judith Heaney5, Hannah Rickman5, Moria Spyer5,8, Daniel Frampton6, Matthew Byott5, Tulio de Oliveira9,10,11,12, Alex Sigal9,13,14, Svend Kjaer15, Charles Swanton16, Sonia Gandhi17, Rupert Beale18, Steve J Gamblin19, John W McCauley4, Rodney Stuart Daniels4, Michael Howell3, David Bauer7, Eleni Nastouli1,5,8, George Kassiotis1,20* 1Retroviral Immunology, London, United Kingdom; 2National Heart and Lung Institute, Imperial College London, London, United Kingdom; 3High Throughput Screening STP, London, United Kingdom; 4Worldwide Influenza Centre, London, United Kingdom; 5Advanced Pathogen Diagnostics Unit UCLH NHS Trust, London, United Kingdom; 6Division of Infection and Immunity, London, United Kingdom; 7RNA Virus Replication Laboratory, London, United Kingdom; 8Department of Population, Policy and Practice, London, United Kingdom; 9School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; 10KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; 11Centre for the AIDS Programme of Research in South Africa, Durban, South Africa; 12Department of Global Health, University of Washington, Seattle, *For correspondence: United States; 13Africa Health Research
    [Show full text]
  • 1339.Full.Pdf
    RESEARCH CORONAVIRUS S7) and was likely the main target of cross- reactive antibodies. Competition with re- Preexisting and de novo humoral immunity combinant soluble S1 or S2 at doses that blocked binding of specific monoclonal anti- to SARS-CoV-2 in humans bodies (fig. S8) did not affect the frequency of cells stained with COVID-19 patient sera, Kevin W. Ng1*, Nikhil Faulkner1*, Georgina H. Cornish1*, Annachiara Rosa2*, Ruth Harvey3, although the intensity of staining was re- Saira Hussain3, Rachel Ulferts9, Christopher Earl4, Antoni G. Wrobel5, Donald J. Benton5, duced by 31 and 37%, respectively (Fig. 1, B Chloe Roustan6, William Bolland1, Rachael Thompson1, Ana Agua-Doce7, Philip Hobson7, to D), indicating recognition of both S1 and Judith Heaney13, Hannah Rickman13, Stavroula Paraskevopoulou13, Catherine F. Houlihan13,14, S2. By contrast, soluble S2 completely abol- Kirsty Thomson13, Emilie Sanchez13, Gee Yen Shin13, Moira J. Spyer13,15, Dhira Joshi8, Nicola O’Reilly8, ished staining with SARS-CoV-2–uninfected Philip A. Walker6, Svend Kjaer6, Andrew Riddell7, Catherine Moore16, Bethany R. Jebson17,19, patient sera, whereas soluble S1 had no effect Meredyth Wilkinson17,19, Lucy R. Marshall17,19, Elizabeth C. Rosser17,18, Anna Radziszewska17,18, (Fig. 1, B to D). Thus, SARS-CoV-2–uninfected Hannah Peckham17,18, Coziana Ciurtin17,18, Lucy R. Wedderburn17,19, Rupert Beale9, Charles Swanton10, patient sera cross-react with SARS-CoV-2 Sonia Gandhi11, Brigitta Stockinger12, John McCauley3, Steve J. Gamblin5, Laura E. McCoy14†, S2, and COVID-19 patient sera additionally Peter Cherepanov2†, Eleni Nastouli13,15†, George Kassiotis1,20† recognize S1. SARS-CoV-2 S–reactive IgG antibodies were Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans.
    [Show full text]
  • Parkinson's UK College of Experts Members
    Parkinson’s UK College of Experts Members Professor Richard Reynolds (Chair) Professor of Cellular Neurobiology, Imperial College London Profile of Professor Richard Reynolds Professor Dag Aarsland Chair of Old Age Psychiatry, King's College London Profile of Dag Aarsland Professor Andrey Abramov Cell Physiology and Pathology, University College London Profile of Andrey Abramov Dr Kambiz Alavian Department of Brain Sciences, Imperial College London Profile of Kambiz Alavian Professor Ann Ashburn Professor of Rehabilitation, University of Southampton Dr Lydia Alvarez-Erviti Principal Investigator, Molecular Neurobiology, Center for Biomedical Research of La Rioja Profile of Lydia Alvarez-Erviti Dr Oleg Anichtchik Lecturer in Clinical Neurobiology, Plymouth University Profile of Oleg Anichtchik Professor Oliver Bandmann Professor of Movement Disorders Neurology, University of Sheffield Profile of Oliver Bandmann Dr Rina Bandopadhyay Senior Fellow and Honorary Lecturer, UCL Institute of Neurology Profile of Dr Rina Bandopadhyay November 2020 Professor Roger Barker Department of Clinical Neurosciences, Cambridge University Profile of Roger Barker Dr Erwan Bezard University of Bordeaux Profile of Erwan Bezard Dr Jose Bras Research Fellow, UCL Institute of Neurology Profile of Dr Jose Bras Dr David Breen Senior Clinical Research Fellow, University of Edinburgh Profile of David Breen Professor David Brown Department of Biology & Biochemistry, University of Bath Profile of David Brown Professor Richard Brown Professor of Neuropsychology and Clinical
    [Show full text]
  • Testing-Webinar-Slides-10042020.Pdf
    Webinar: Opportunities to contribute to the National Diagnostics Effort for COVID-19 Our national effort for diagnostics Rt Hon Matthew Hancock MP Secretary of State for Health and Social Care 2 Today’s Agenda 12:25-12:35 Dr Sam Roberts - Director of Testing Supplies Our national approach 12:35-12:55 Dr Beverley Jandziol – Government Commercial Lead for the Testing Programme Our needs for pillar 1 & 2: Consumables: Prof Chris Molloy –Co-Ordinator of the National Hub Labs and CEO of the Medicines Discovery Catapult Mark Stevenson – Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific Q&A 12:55-13:15 David Wells – Head of Pathology, COVID-19 Testing Cell Our needs for pillars 1& 2: enabling open RNA extraction and Ewan Cameroon – South of England Head of Diagnostics, NHS England and Improvement PCR platforms alongside NHS labs Dr Sonia Gandhi – The Francis Crick Institute Q&A 13.15 – 13.20 Paul Chambers – Department of Health and Social Care How to respond and our future communication 13:20-13:40 Prof Jo Martin – President of the Royal College of Pathologists Pillar 5: Developing the UK’s Q&A diagnostics industry - call for novel solutions in key areas 13:40-13:45 Dr Sam Roberts – Director of Testing Supplies Close 3 What we need from you Update on our National Testing Strategy Dr Sam Roberts Director of Testing Supply 4 Our National Testing Strategy ‘Pillar 1’ : Scaling up NHS swab testing for those with a medical need and, where possible, the most critical key workers ‘Pillar 2’: Mass-swab testing for critical
    [Show full text]
  • Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP- Related ALS
    Report Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP- Related ALS Graphical Abstract Authors Claire E. Hall, Zhi Yao, Minee Choi, ..., Jernej Ule, Sonia Gandhi, Rickie Patani Correspondence [email protected] (S.G.), [email protected] (R.P.) In Brief Hall et al. use iPSCs to examine the sequence of events by which motor neurons degenerate in a genetic form of ALS. They find that astrocytes, a type of supportive cell, also degenerate under these conditions. The ALS-causing mutation disrupts the ability of astrocytes to promote survival of motor neurons. Highlights Accession Numbers d Robust and enriched motor neurogenesis and GSE98288 astrogliogenesis from human iPSCs d VCP-mutant motor neurons show TDP-43 mislocalization and ER stress as early pathogenic events d VCP-mutant astrocytes exhibit a cell-autonomous survival phenotype d VCP-mutations perturb the ability of astrocytes to support motor neuron survival Hall et al., 2017, Cell Reports 19, 1739–1749 May 30, 2017 ª 2017 The Authors. http://dx.doi.org/10.1016/j.celrep.2017.05.024 Cell Reports Report Progressive Motor Neuron Pathology and the Role of Astrocytes in a Human Stem Cell Model of VCP-Related ALS Claire E. Hall,1,11 Zhi Yao,2,11 Minee Choi,2,11 Giulia E. Tyzack,1,11 Andrea Serio,3 Raphaelle Luisier,4,5 Jasmine Harley,1,2 Elisavet Preza,1 Charlie Arber,1 Sarah J. Crisp,6 P. Marc D. Watson,7 Dimitri M. Kullmann,6 Andrey Y. Abramov,1 Selina Wray,1 Russell Burley,7 Samantha H.Y.
    [Show full text]
  • Alpha Synuclein Aggregation Drives Ferroptosis: an Interplay of Iron, Calcium and Lipid Peroxidation
    Cell Death & Differentiation (2020) 27:2781–2796 https://doi.org/10.1038/s41418-020-0542-z ARTICLE Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation 1 1,2 3,4 5,6 6 Plamena R. Angelova ● Minee L. Choi ● Alexey V. Berezhnov ● Mathew H. Horrocks ● Craig D. Hughes ● 6,7 6,7 8 9,10 8 8 Suman De ● Margarida Rodrigues ● Ratsuda Yapom ● Daniel Little ● Karamjit S. Dolt ● Tilo Kunath ● 9 9,10 11 1,12 13 Michael J. Devine ● Paul Gissen ● Mikhail S. Shchepinov ● Sergiy Sylantyev ● Evgeny V. Pavlov ● 6,7 1,4 1,2 David Klenerman ● Andrey Y. Abramov ● Sonia Gandhi Received: 19 September 2019 / Revised: 1 April 2020 / Accepted: 3 April 2020 / Published online: 27 April 2020 © The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare 2020. This article is published with open access Abstract Protein aggregation and abnormal lipid homeostasis are both implicated in neurodegeneration through unknown mechanisms. Here we demonstrate that aggregate-membrane interaction is critical to induce a form of cell death called ferroptosis. Importantly, the aggregate-membrane interaction that drives ferroptosis depends both on the conformational structure of the aggregate, as well as the oxidation state of the lipid membrane. We generated human stem cell-derived α 1234567890();,: 1234567890();,: models of synucleinopathy, characterized by the intracellular formation of -synuclein aggregates that bind to membranes. In human iPSC-derived neurons with SNCA triplication, physiological concentrations of glutamate and dopamine induce abnormal calcium signaling owing to the incorporation of excess α-synuclein oligomers into membranes, leading to altered membrane conductance and abnormal calcium influx.
    [Show full text]
  • An Interplay of Iron, Calcium and Lipid 1 Peroxidation 2 Plamena R
    1 Title: Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid 2 peroxidation 3 Plamena R. Angelova1#, Minee L. Choi1,8#, Alexey V. Berezhnov2,11, Mathew H. Horrocks7, Craig D. 4 Hughes7, Suman De7,10, Margarida Rodrigues7,10, Ratsuda Yapom3, Daniel Little4,12, Karamjit S. 5 Dolt3, Tilo Kunath3, Michael J. Devine4, Paul Gissen4,12, Mikhail S. Shchepinov9, Sergiy Sylantyev1,5, 6 Evgeny V. Pavlov6, David Klenerman7,10, Andrey Y. Abramov1,11*, Sonia Gandhi1,8* 7 1UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK; 2Institute of Cell Biophysics, Russian 8 Academy of Sciences, Pushchino, 142290, Russia; 3MRC Centre for Regenerative Medicine, The University 9 of Edinburgh, Edinburgh, UK; 4MRC Laboratory for Molecular Cell Biology, University College London, 10 Gower Street, London, UK; 5Rowett Institute, University of Aberdeen, Ashgrove Rd West, Aberdeen AB25 11 2ZD, UK; 6College of Dentistry, New York University, New York, USA; 7 Department of Chemistry, 12 University of Cambridge, Cambridge, UK; 8The Francis Crick Institute, London, UK; 9 Retrotope Inc., Los 13 Altos, California 94022, United States; 10Dementia Research institute at University of Cambridge, 14 Cambridge, UK; 11Orel State University, Orel, Russia, 12NIHR Great Ormond Street Hospital Biomedical 15 Research Centre, London, UK. 16 17 # Equally contributing author. 18 * Joint senior authors. 19 To whom correspondence should be addressed: Andrey Y. Abramov or Sonia Gandhi, UCL Institute of 20 Neurology, Queen Square House, Queen Square, London, UK, WC1N 3BG, 21 Tel.: (+44) 203 448 4062; E-mail: [email protected] ; [email protected] 22 23 Keywords: alpha-synuclein, calcium signalling, synucleinopathy, Parkinson’s disease, Ferroptosis, iPSC- 24 derived neurons, electrophysiology 25 26 Abstract 27 Protein aggregation and abnormal lipid homeostasis are both implicated in neurodegeneration through 28 unknown mechanisms.
    [Show full text]
  • Lipid Peroxidation Is Essential for Α-Synuclein-Induced Cell Death
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Research Online University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2015 Lipid peroxidation is essential for α-synuclein- induced cell death Plamena R. Angelova UCL Institute of Neurology Mathew H. Horrocks University of Cambridge, [email protected] David Klenerman University of Cambridge Sonia Gandhi UCL Institute of Neurology Andrey Y. Abramov University College London See next page for additional authors Publication Details Angelova, P. R., Horrocks, M. H., Klenerman, D., Gandhi, S., Abramov, A. Y. & Shchepinov, M. S. (2015). Lipid peroxidation is essential for α-synuclein-induced cell death. Journal of Neurochemistry, 133 (4), 582-589. Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [email protected] Lipid peroxidation is essential for α-synuclein-induced cell death Abstract Parkinson's disease is the second most common neurodegenerative disease and its pathogenesis is closely associated with oxidative stress. Deposition of aggregated α-synuclein (α-Syn) occurs in familial and sporadic forms of Parkinson's disease. Here, we studied the effect of oligomeric α-Syn on one of the major markers of oxidative stress, lipid peroxidation, in primary co-cultures of neurons and astrocytes. We found that oligomeric but not monomeric α-Syn significantly increases the rate of production of reactive oxygen species, subsequently inducing lipid peroxidation in both neurons and astrocytes. Pre-incubation of cells with isotope- reinforced polyunsaturated fatty acids (D-PUFAs) completely prevented the effect of oligomeric α-Syn on lipid peroxidation.
    [Show full text]
  • Nanoscopic Characterization of Individual Endogenous Protein Aggregates in Human Neuronal Cells
    Edinburgh Research Explorer Nanoscopic characterization of individual endogenous protein aggregates in human neuronal cells Citation for published version: Horrocks, M, Whiten, DR, Zuo, Y, Calo, L, Choi, M, De, S, Wirthensohn, DC, Kundel, F, Lee, SF, Dobson, C, Gandhi, S, Spillantini, M, Klenerman, D, Ranasinghe, RT, Sanchez, SE, Athauda, D & Flagmeier, P 2018, 'Nanoscopic characterization of individual endogenous protein aggregates in human neuronal cells', ChemBioChem. https://doi.org/10.1002/cbic.201800209 Digital Object Identifier (DOI): 10.1002/cbic.201800209 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: ChemBioChem General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 COMMUNICATION Nanoscopic characterization of individual endogenous protein aggregates in human neuronal cells Daniel R. Whiten†, Yukun Zuo†, Laura Calo, Minee-Liane Choi, Suman De, Patrick Flagmeier, David C. Wirthensohn, Franziska Kundel, Rohan T. Ranasinghe, Santiago E. Sanchez, Dilan Athauda, Steven F. Lee, Christopher M. Dobson, Sonia Gandhi, Maria-Grazia Spillantini, David Klenerman*, Mathew H. Horrocks†* Abstract: The aberrant misfolding and subsequent conversion of monomeric protein into amyloid aggregates characterizes many neurodegenerative disorders, including Parkinson’s and Alzheimer’s diseases.
    [Show full text]
  • 2020.06.08.20120584V1.Full.Pdf
    medRxiv preprint doi: https://doi.org/10.1101/2020.06.08.20120584; this version posted June 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal study Running title SARS-CoV-2 incidence in Health Care Workers 1. Catherine F Houlihan, PhD, Dept Clinical Virology at UCLH, Department infection and Immunity at UCL, Department of Clinical Research at LSHTM, London, UK 2. Nina Vora, MBBS, Institute for Global Health, University College London, London, UK 3. Thomas Byrne, MPH University College London Great Ormond Street Institute of Child Health, London, UK 4. Dan Lewer MSc, Institute of Epidemiology and Healthcare, University College London, London, UK 5. Judith Heaney, PhD, Advanced Pathology Diagnostic Unit, UCLH and University College London Great Ormond Street Institute of Child Health, London, UK 6. David A. Moore, MD, Cancer Research UK Lung Cancer Centre of Excellence, University College , London Cancer Institute, London; Department of Cellular Pathology, University College London, University College Hospital, London, UK 7. Rebecca Matthews, BSc, Institute for Global Health, University College London, London, UK 8. Sajida Adam BSc, Cancer Clinical Trials Unit, University College London Hospital, London, UK 9. Louise Enfield , PhD, Cancer Clinical Trials Unit, University College London Hospital, London, UK 10. Abigail Severn MSc, Institute for Global Health, University College London, London, UK 11.
    [Show full text]